The following is a summary of “Initial experience of a novel ureteral silicon-covered metallic mesh stent in malignant ureteric obstruction: a single-center retrospective study,” published in the December 2024 issue of Urology by Lee et al.
Researchers conducted a retrospective study to assess the initial experiences and outcomes of the retrograde insertion of a silicone-covered metallic ureteric stent (Urexel™ ) for malignant ureteric obstruction.
They reviewed the medical records of 12 patients who received Urexel™ stent placement for malignant ureteric obstruction from March 2020 to March 2021. Clinical outcomes and complications of the nitinol mesh stent covered with silicone were assessed.
The results showed a median patient age of 61.5 (44–82) years and a median follow-up of 25.5 (4–37) months. The 1 patient had bilateral stent insertion, with 13 ureteral units treated. No technical failure occurred during placement. The median obstruction length was 9 (1–22) cm. Balloon dilation was needed in 38.5% (5/13) cases. The 6-month success rate was 83.3%, 1-year success rate was 70%, and 2-year success rate was 44.4%. Encrustation, migration, and hyperplasia caused failure in all 6 cases, with a median time to failure of 9.5 (1–30) months. Common complications were persistent pain, acute pyelonephritis, and lower urinary tract symptoms, all Clavien-Dindo grade I or II.
Investigators concluded that Urexel™ silicone-covered metallic mesh stents provided acceptable success and complication rates in malignant ureteric obstructions. The stents demonstrated promising outcomes in this initial series.
Source: bmcurol.biomedcentral.com/articles/10.1186/s12894-024-01653-y
The post Outcomes of Silicone-Covered Metallic Mesh Stent in Malignant Ureteric Obstruction first appeared on Physician's Weekly.